Revance Therapeutics (NASDAQ:RVNC) released its earnings results on Monday. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, meeting the consensus estimate of ($0.86), Bloomberg Earnings reports. Revance Therapeutics had a negative net margin of 3,745.97% and a negative return on equity of 75.31%.
Shares of Revance Therapeutics stock traded up $0.33 during trading on Tuesday, hitting $12.27. 355,695 shares of the stock were exchanged, compared to its average volume of 365,972. The company has a fifty day moving average of $12.30. The stock has a market cap of $525.48 million, a PE ratio of -3.11 and a beta of 1.00. The company has a current ratio of 8.13, a quick ratio of 8.13 and a debt-to-equity ratio of 0.13. Revance Therapeutics has a 12 month low of $10.37 and a 12 month high of $27.95.
Several institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc grew its position in shares of Revance Therapeutics by 21.7% during the fourth quarter. Legal & General Group Plc now owns 6,445 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 1,150 shares during the last quarter. Edge Wealth Management LLC grew its position in shares of Revance Therapeutics by 550.0% during the first quarter. Edge Wealth Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 2,750 shares during the last quarter. FNY Investment Advisers LLC bought a new position in shares of Revance Therapeutics during the second quarter worth about $37,000. Swiss National Bank grew its position in shares of Revance Therapeutics by 5.6% during the second quarter. Swiss National Bank now owns 73,350 shares of the biopharmaceutical company’s stock worth $951,000 after acquiring an additional 3,900 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its position in shares of Revance Therapeutics by 36.7% during the second quarter. State Board of Administration of Florida Retirement System now owns 15,712 shares of the biopharmaceutical company’s stock worth $204,000 after acquiring an additional 4,220 shares during the last quarter. Institutional investors and hedge funds own 94.81% of the company’s stock.
About Revance Therapeutics
Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.
Featured Article: How to use beta for portfolio diversification
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.